{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T20:46:56Z","timestamp":1792874816389,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,28]]},"DOI":"10.7759\/cureus.33070","type":"journal-article","created":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T05:47:12Z","timestamp":1672292832000},"source":"Crossref","is-referenced-by-count":2,"title":["Assessment of the Safety, Efficacy, and Benefit of Empagliflozin in Patients With Type 2 Diabetes Mellitus (T2DM) and Heart Failure With Reduced Ejection Fraction (HFrEF) at High Risk for Cardiovascular Events"],"prefix":"10.7759","author":[{"given":"Ruba","family":"Towiargi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lama","family":"Fetyani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naila","family":"Aljahdali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Alnofeie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahya","family":"Alnoamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reham","family":"Ghandorah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abrar","family":"Abduljawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Njood","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alanoud","family":"Alghanmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hala","family":"AlButi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.7008","article-title":"Association of cardiometabolic multimorbidity with mortality","volume":"314","author":"Di Angelantonio E","year":"2015","unstructured":"Di Angelantonio E, Kaptoge S, Wormser D, et al.. Association of cardiometabolic multimorbidity with mortality. JAMA. 2015, 314:52-60. 10.1001\/jama.2015.7008","journal-title":"JAMA"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.15537\/smj.2021.42.5.20200676","article-title":"Prevalence and reasons of increased type 2 diabetes in Gulf Cooperation Council Countries","volume":"42","author":"Aljulifi MZ","year":"2021","unstructured":"Aljulifi MZ. Prevalence and reasons of increased type 2 diabetes in Gulf Cooperation Council Countries. Saudi Med J. 2021, 42:481-90. 10.15537\/smj.2021.42.5.20200676","journal-title":"Saudi Med J"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.12816\/0024690","article-title":"Burden of diabetes mellitus in Saudi Arabia","volume":"9","author":"Naeem Z","year":"2015","unstructured":"Naeem Z. Burden of diabetes mellitus in Saudi Arabia. Int J Health Sci (Qassim). 2015, 9:V-VI. 10.12816\/0024690","journal-title":"Int J Health Sci (Qassim)"},{"key":"ref4","doi-asserted-by":"crossref","DOI":"10.2174\/1573399811666150724095130","article-title":"Diabetes mellitus in Saudi Arabia: a review of the recent literature","volume":"12","author":"Abdulaziz Al Dawish M","year":"2016","unstructured":"Abdulaziz Al Dawish M, Alwin Robert A, Braham R, et al.. Diabetes mellitus in Saudi Arabia: a review of the recent literature. Curr Diabetes Rev. 2016, 12:359-68.","journal-title":"Curr Diabetes Rev"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14042","article-title":"Management of heart failure and type 2 diabetes mellitus: maximizing complementary drug therapy","volume":"22","author":"Butler J","year":"2020","unstructured":"Butler J, Januzzi JL, Rosenstock J. Management of heart failure and type 2 diabetes mellitus: maximizing complementary drug therapy. Diabetes Obes Metab. 2020, 22:1243-62. 10.1111\/dom.14042","journal-title":"Diabetes Obes Metab"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2018.04.005","article-title":"National trends in diabetes mellitus hospitalization in Spain 1997-2010: analysis of over 5.4 millions of admissions","volume":"60","author":"Lara-Rojas CM","year":"2019","unstructured":"Lara-Rojas CM, P\u00e9rez-Belmonte LM, L\u00f3pez-Carmona MD, Guijarro-Merino R, Bernal-L\u00f3pez MR, G\u00f3mez-Huelgas R. National trends in diabetes mellitus hospitalization in Spain 1997-2010: analysis of over 5.4 millions of admissions. Eur J Intern Med. 2019, 60:83-9. 10.1016\/j.ejim.2018.04.005","journal-title":"Eur J Intern Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/1479164114561992","article-title":"Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences","volume":"12","author":"Gallo LA","year":"2015","unstructured":"Gallo LA, Wright EM, Vallon V. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diab Vasc Dis Res. 2015, 12:78-89. 10.1177\/1479164114561992","journal-title":"Diab Vasc Dis Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3934\/medsci.2018.1.67","article-title":"Impact of SGLT2i on cardiovascular outcomes and heart failure in patients with type 2 diabetes","volume":"5","author":"Juan Jose\u0301 RG","year":"2018","unstructured":"Juan Jose\u0301 RG, Luis OP, Salvatore B, Manel S. Impact of SGLT2i on cardiovascular outcomes and heart failure in patients with type 2 diabetes. AIMS Med Sci. 2018, 5:67-79. 10.3934\/medsci.2018.1.67","journal-title":"AIMS Med Sci"},{"key":"ref9","article-title":"Jardiance (Empagliflozin), an SGLT2 inhibitor, receives FDA approval for the treatment of patients with type 2 diabetes","volume":"8","author":"Fala L","year":"2015","unstructured":"Fala L. Jardiance (Empagliflozin), an SGLT2 inhibitor, receives FDA approval for the treatment of patients with type 2 diabetes. Am Health Drug Benefits. 2015, 8:92-5.","journal-title":"Am Health Drug Benefits"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2673","article-title":"Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial","volume":"36","author":"H\u00e4ring HU","year":"2013","unstructured":"H\u00e4ring HU, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Woerle HJ, Broedl UC. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2013, 36:3396-404. 10.2337\/dc12-2673","journal-title":"Diabetes Care"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2105","article-title":"Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial","volume":"37","author":"H\u00e4ring HU","year":"2014","unstructured":"H\u00e4ring HU, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Broedl UC, Woerle HJ. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2014, 37:1650-9. 10.2337\/dc13-2105","journal-title":"Diabetes Care"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12188","article-title":"Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial","volume":"16","author":"Kovacs CS","year":"2014","unstructured":"Kovacs CS, Seshiah V, Swallow R, Jones R, Rattunde H, Woerle HJ, Broedl UC. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab. 2014, 16:147-58. 10.1111\/dom.12188","journal-title":"Diabetes Obes Metab"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(13)70084-6","article-title":"Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"1","author":"Roden M","year":"2013","unstructured":"Roden M, Weng J, Eilbracht J, et al.. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2013, 1:208-19. 10.1016\/S2213-8587(13)70084-6","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-3055","article-title":"Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes","volume":"37","author":"Rosenstock J","year":"2014","unstructured":"Rosenstock J, Jelaska A, Frappin G, Salsali A, Kim G, Woerle HJ, Broedl UC. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care. 2014, 37:1815-23. 10.2337\/dc13-3055","journal-title":"Diabetes Care"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12503","article-title":"Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial","volume":"17","author":"Rosenstock J","year":"2015","unstructured":"Rosenstock J, Jelaska A, Zeller C, Kim G, Broedl UC, Woerle HJ. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2015, 17:936-48. 10.1111\/dom.12503","journal-title":"Diabetes Obes Metab"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1096","article-title":"Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension","volume":"38","author":"Tikkanen I","year":"2015","unstructured":"Tikkanen I, Narko K, Zeller C, Green A, Salsali A, Broedl UC, Woerle HJ. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015, 38:420-8. 10.2337\/dc14-1096","journal-title":"Diabetes Care"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(13)70208-0","article-title":"Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Barnett AH","year":"2014","unstructured":"Barnett AH, Mithal A, Manassie J, et al.. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2014, 2:369-84. 10.1016\/S2213-8587(13)70208-0","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman B","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al.. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015, 373:2117-28. 10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1177\/1179551418786258","article-title":"Combination of empagliflozin and metformin therapy: a consideration of its place in type 2 diabetes therapy","volume":"11","author":"Goldman JD","year":"2018","unstructured":"Goldman JD. Combination of empagliflozin and metformin therapy: a consideration of its place in type 2 diabetes therapy. Clin Med Insights Endocrinol Diabetes. 2018, 11:1179551418786258. 10.1177\/1179551418786258","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"key":"ref20","article-title":"Empagliflozin (Jardiance): a novel SGLT2 inhibitor for the treatment of type-2 diabetes","volume":"40","author":"Ndefo UA","year":"2015","unstructured":"Ndefo UA, Anidiobi NO, Basheer E, Eaton AT. Empagliflozin (Jardiance): a novel SGLT2 inhibitor for the treatment of type-2 diabetes. P T. 2015, 40:364-8.","journal-title":"P T"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.15590","article-title":"Multimorbidity burden and adverse outcomes in a community\u2010based cohort of adults with heart failure","volume":"66","author":"Tisminetzky M","year":"2018","unstructured":"Tisminetzky M, Gurwitz JH, Fan D, et al.. Multimorbidity burden and adverse outcomes in a community\u2010based cohort of adults with heart failure. J Am Geriatr Soc. 2018, 66:2305-13. 10.1111\/jgs.15590","journal-title":"J Am Geriatr Soc"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/ph15010047","article-title":"Empagliflozin-a new chance for patients with chronic heart failure","volume":"15","author":"Kowalska K","year":"2021","unstructured":"Kowalska K, Walczak J, Femlak J, M\u0142ynarska E, Franczyk B, Rysz J. Empagliflozin-a new chance for patients with chronic heart failure. Pharmaceuticals (Basel). 2021, 15:10.3390\/ph15010047","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.72772","article-title":"Empagliflozin in the treatment of heart failure and type 2 diabetes mellitus: evidence from several large clinical trials","volume":"19","author":"Liang B","year":"2022","unstructured":"Liang B, Gu N. Empagliflozin in the treatment of heart failure and type 2 diabetes mellitus: evidence from several large clinical trials. Int J Med Sci. 2022, 19:1118-21. 10.7150\/ijms.72772","journal-title":"Int J Med Sci"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.683281","article-title":"Empagliflozin in patients with heart failure: a systematic review and meta-analysis of randomized controlled trials","volume":"8","author":"Pan D","year":"2021","unstructured":"Pan D, Xu L, Chen P, Jiang H, Shi D, Guo M. Empagliflozin in patients with heart failure: a systematic review and meta-analysis of randomized controlled trials. Front Cardiovasc Med. 2021, 8:683281. 10.3389\/fcvm.2021.683281","journal-title":"Front Cardiovasc Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.037778","article-title":"Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial","volume":"139","author":"Fitchett D","year":"2019","unstructured":"Fitchett D, Inzucchi SE, Cannon CP, et al.. Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial. Circulation. 2019, 139:1384-95. 10.1161\/CIRCULATIONAHA.118.037778","journal-title":"Circulation"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.051783","article-title":"Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial","volume":"143","author":"Packer M","year":"2021","unstructured":"Packer M, Anker SD, Butler J, et al.. Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. Circulation. 2021, 143:326-36. 10.1161\/CIRCULATIONAHA.120.051783","journal-title":"Circulation"},{"key":"ref27","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray JJV","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al.\r\nSchulze PC, Wu JM. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019, 381:1995-2008.","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer M","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al.. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020, 383:1413-24. 10.1056\/NEJMoa2022190","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1101\/2022.05.23.22275457","article-title":"Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes","author":"Lim J","year":"2022","unstructured":"Lim J, Hwang IC, Choi HM, Yoon YE, Cho GY. Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes. MedRxiv. 2022, 10.1101\/2022.05.23.22275457","journal-title":"MedRxiv"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10163540","article-title":"Efficacy and safety of empagliflozin continuation in patients with type 2 diabetes hospitalised for acute decompensated heart failure","volume":"10","author":"P\u00e9rez-Belmonte LM","year":"2021","unstructured":"P\u00e9rez-Belmonte LM, Ricci M, Sanz-C\u00e1novas J, et al.. Efficacy and safety of empagliflozin continuation in patients with type 2 diabetes hospitalised for acute decompensated heart failure. J Clin Med. 2021, 10:10.3390\/jcm10163540","journal-title":"J Clin Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.14744\/nci.2019.22697","article-title":"The effect of low and high dose empagliflozin on HbA1c and lipid profile in type 2 diabetes mellitus: a real-world data","volume":"7","author":"Ozcelik S","year":"2020","unstructured":"Ozcelik S, Celik M, Vural A, Aydin B. The effect of low and high dose empagliflozin on HbA1c and lipid profile in type 2 diabetes mellitus: a real-world data. North Clin Istanb. 2020, 7:167-73. 10.14744\/nci.2019.22697","journal-title":"North Clin Istanb"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1177\/1179551419866811","article-title":"Potential impact on lipoprotein subfractions in type 2 diabetes","volume":"12","author":"Kamijo Y","year":"2019","unstructured":"Kamijo Y, Ishii H, Yamamoto T, et al.. Potential impact on lipoprotein subfractions in type 2 diabetes. Clin Med Insights Endocrinol Diabetes. 2019, 12:1179551419866811. 10.1177\/1179551419866811","journal-title":"Clin Med Insights Endocrinol Diabetes"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/119969-assessment-of-the-safety-efficacy-and-benefit-of-empagliflozin-in-patients-with-type-2-diabetes-mellitus-t2dm-and-heart-failure-with-reduced-ejection-fraction-hfref-at-high-risk-for-cardiovascular-events","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:48:01Z","timestamp":1707508081000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/119969-assessment-of-the-safety-efficacy-and-benefit-of-empagliflozin-in-patients-with-type-2-diabetes-mellitus-t2dm-and-heart-failure-with-reduced-ejection-fraction-hfref-at-high-risk-for-cardiovascular-events"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,28]]},"references-count":32,"URL":"https:\/\/doi.org\/10.7759\/cureus.33070","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12,28]]}}}